Table 2.
Prevalence of IgG antibodies reacting to SV40 Tag mimotopes in serum samples from OS patients, treated and untreated, compared to HS.
| Serum | Number of patients/individuals | Mean age (Range) years | Male, % | Number of SV40 Tag- positive samples (%) | |||
|---|---|---|---|---|---|---|---|
| Tag A | Tag D | Tag (A+D) | |||||
| OS | 249 | 22 (6–76) | 56 | 94 (38) | 99 (40) | 87 (35)* | |
| Treated | 166 | 21 (6–62) | 55 | 61 (37) | 67 (41) | 56 (34)° | |
| Untreated | 83 | 25 (8–76) | 58 | 33 (40) | 32 (39) | 31 (37)§ | |
| Outcome | |||||||
| No metastasis | 83 | 25 (8–76) | 58 | 54 (36) | 56 (38) | 49 (33) | |
| Metastasis | 100 | 21 (6–72) | 53 | 40 (40) | 43 (43) | 38 (38) | |
| Dead | 105 | 24 (7–76) | 66 | 42 (40) | 45 (43) | 37 (35) | |
| HS | 247 | 21 (4–76) | 47 | 63 (26) | 63 (26) | 56 (23) | |
OS, osteosarcoma; HS, healthy subjects; SV40, simian virus 40. The different prevalence of SV40 Tag antibodies in osteosarcoma OS patients was statistically significant compared to HS (*P < 0.01).
The different prevalence of SV40 Tag antibodies in OS patients, either treated with chemotherapy or without treatment, were statistically significant compared to HS (§°P < 0.05).
P values were determined using the Chi-square with Yates' correction.